P2RX7 Protein

Overview

The P2X7 receptor (P2X purinoceptor 7) is an ATP-gated cation channel that occupies a unique position among purinergic receptors due to its dual function as both a rapid ion channel and a macropore-forming complex^{1The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7)1996 · Science · PMID 8637576Open reference}. Unlike other P2X family members, P2X7 requires millimolar concentrations of extracellular ATP for activation — concentrations typically reached only during cellular stress, injury, or death — making it a danger signal sensor in the central nervous system^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}. P2X7 is predominantly expressed on microglia, astrocytes, and oligodendrocytes, with lower expression on neurons, positioning it as a master regulator of neuroinflammation^{3P2X7 receptor in the brain: role in neuroinflammation and neurodegeneration2020 · Purinergic Signalling · PMID 32165058Open reference}.

In the context of neurodegeneration, P2X7 activation triggers the NLRP3 inflammasome assembly, leading to caspase-1-dependent maturation and release of pro-inflammatory cytokines IL-1β and IL-18, as well as pyroptotic cell death via gasdermin D pore formation^{4The NLRP3 inflammasome: molecular activation and regulation to therapeutics2019 · Nature Reviews Immunology · PMID 31048789Open reference}. This pathway is critically implicated in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, and Huntington’s disease^{5An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration2016 · Neuropharmacology · PMID 26946438Open reference}.

Structure

Domain Architecture

P2X7 is a 595-amino-acid protein with a distinctive topology consisting of:

• Intracellular N-terminus (26 residues): Contains a conserved protein kinase C phosphorylation site (T18) that modulates channel gating

• First transmembrane domain (TM1): Contributes to the ion conduction pathway and intersubunit contacts

• Large extracellular loop (~280 residues): Contains the ATP-binding site at subunit interfaces, stabilized by five conserved disulfide bonds (C119–C168, C130–C159, C149–C163, C217–C227, C260–C267), and houses N-glycosylation sites at N187, N202, N213, N241, and N284

• Second transmembrane domain (TM2): Lines the ion pore; critical residues include T339 and S342 for ion selectivity

• Extended C-terminal tail (~240 residues): The longest among P2X family members, essential for macropore formation, protein-protein interactions, and signaling scaffold function^{6Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization2019 · Cell · PMID 31160782Open reference}

Homotrimeric Assembly

P2X7 functions as a homotrimer, with three ATP-binding sites located at subunit interfaces. The crystal structure of the panda P2X7 ectodomain (PDB: 5U1L) revealed a chalice-shaped architecture with each subunit resembling a dolphin, consistent with other P2X receptor structures^{7Structural basis for subtype-specific inhibition of the P2X7 receptor2016 · eLife · PMID 27626380Open reference}. Upon ATP binding, the receptor undergoes conformational changes that open a cation-selective channel within milliseconds; sustained ATP application (seconds to minutes) induces a secondary dilation to a macropore permeable to molecules up to ~900 Da^{8Macropore formation and the role of the C-terminal domain of P2X72008 · Purinergic Signalling · PMID 17996911Open reference}.

Post-Translational Modifications

• Palmitoylation: C-terminal cysteines (C371, C373, C374, C477, C479, C482, C498, C499, C506, C572, C573) are palmitoylated, anchoring the C-terminus to the membrane and enabling macropore formation

• Phosphorylation: T18 (PKC), Y343 (Src family kinases) regulate channel activity

• ADP-ribosylation: In murine P2X7, ecto-ART2.2 modifies R125, providing an alternative NAD-dependent activation pathway^{9Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation2016 · Science Translational Medicine · PMID 27426735Open reference}

Normal Function in the Nervous System

Microglial Surveillance

P2X7 is the most abundantly expressed purinergic receptor on microglia. At resting state, low-level P2X7 signaling contributes to:

• Phagocytic activity: Moderate P2X7 activation enhances microglial phagocytosis of apoptotic debris and synaptic material

• Process motility: ATP gradients detected through P2X7 (and P2Y12) guide microglial surveillance processes toward sites of neuronal activity or damage

• Cytokine homeostasis: Tonic P2X7 signaling maintains baseline IL-1β processing for synaptic plasticity^{10P2X7 receptor and microglial function2012 · Acta Pharmacologica Sinica · PMID 22245795Open reference}

Synaptic Modulation

Although neuronal P2X7 expression remains debated, functional evidence supports roles in:

• Presynaptic glutamate release: P2X7 activation at hippocampal mossy fiber terminals enhances glutamate release

• GABA release modulation: P2X7 on GABAergic terminals in the cerebellum modulates inhibitory transmission

• Long-term potentiation (LTP): P2X7 knockout mice show enhanced LTP at CA1 synapses, suggesting tonic P2X7-mediated suppression of synaptic plasticity^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}0

Oligodendrocyte Biology

P2X7 activation on oligodendrocyte precursor cells (OPCs) promotes differentiation at low ATP concentrations but triggers apoptosis at sustained high concentrations, creating a concentration-dependent switch between myelination and demyelination^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}1.

Role in Neurodegenerative Disease

Alzheimer’s Disease

P2X7 is critically implicated in Alzheimer’s disease pathogenesis through multiple converging mechanisms:

• Amyloid-β-induced activation: Soluble amyloid-β oligomers stimulate ATP release from astrocytes and neurons, creating a feed-forward loop of P2X7 activation on microglia^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}2

• NLRP3 inflammasome activation: P2X7→K⁺ efflux→NLRP3→caspase-1→IL-1β/IL-18 is the primary pathway linking amyloid pathology to neuroinflammation. P2X7 knockout in APP/PS1 mice reduces amyloid plaque burden by ~50% and rescues spatial memory deficits^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}3

• Tau phosphorylation: IL-1β released via P2X7/NLRP3 activates neuronal GSK-3β and CDK5 pathways, promoting tau hyperphosphorylation

• Microglial M1 polarization: Chronic P2X7 activation shifts microglia toward a pro-inflammatory (disease-associated) phenotype with impaired amyloid phagocytosis

• Genetic association: The P2RX7 rs208294 (H155Y) gain-of-function variant is associated with increased AD risk in European populations^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}4

Parkinson’s Disease

In Parkinson’s disease, P2X7 contributes to dopaminergic neuron loss:

• Substantia nigra inflammation: P2X7 expression is upregulated on microglia surrounding degenerating dopaminergic neurons in both MPTP mouse models and human PD brain tissue

• α-Synuclein-mediated activation: Extracellular α-synuclein aggregates trigger microglial ATP release and subsequent P2X7 activation, creating a neuroinflammatory amplification loop

• Pyroptosis: P2X7-dependent caspase-1 activation in microglia promotes pyroptotic cell death, releasing DAMPs that further propagate inflammation^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}5

Amyotrophic Lateral Sclerosis

P2X7 is upregulated in the spinal cord of ALS patients and SOD1-G93A mice:

• Motor neuron vulnerability: P2X7 activation on spinal cord microglia and astrocytes releases toxic factors (TNFα, glutamate, ROS) that damage motor neurons

• Presymptomatic upregulation: P2X7 expression increases before motor neuron degeneration becomes apparent, suggesting a causative role rather than reactive response

• Genetic modifiers: P2RX7 loss-of-function variants are associated with later disease onset in some ALS cohorts^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}6

Multiple Sclerosis

P2X7 mediates oligodendrocyte death and demyelination:

• Excitotoxic oligodendrocyte damage: Sustained P2X7 activation causes Ca²⁺ overload and mitochondrial dysfunction in oligodendrocytes

• EAE models: P2X7 knockout mice show reduced demyelination and clinical scores in experimental autoimmune encephalomyelitis

• Macropore-mediated antigen release: P2X7 macropore formation facilitates release of myelin antigens, potentially driving autoimmune responses^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}7

Huntington’s Disease

In Huntington’s disease, mutant huntingtin aggregates sensitize cells to P2X7 activation:

• Mutant huntingtin expression lowers the ATP threshold for P2X7 macropore formation

• P2X7 antagonism reduces striatal neuron vulnerability in R6/2 mice^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}8

Therapeutic Targeting

P2X7 Antagonists in Development

Compound	Developer	Stage	Notes
JNJ-54175446	Janssen	Phase II (depression)	Brain-penetrant, selective P2X7 antagonist
JNJ-55308942	Janssen	Phase I	Second-generation P2X7 antagonist
AZD9056	AstraZeneca	Phase II (RA)	Limited CNS penetration; discontinued for inflammation
CE-224535	Pfizer	Phase II (RA)	Discontinued
GSK1482160	GSK	Phase I	High CNS penetration; PET tracer developed
Lu AF27139	Lundbeck	Preclinical	Optimized for neuroinflammation

PET Imaging

¹¹CGSK1482160 and ¹⁸FJNJ-64413739 are P2X7-specific PET tracers enabling in vivo quantification of P2X7 expression in neuroinflammatory conditions. Studies in AD patients show elevated P2X7 binding in temporal and parietal cortices correlating with amyloid burden^{2The P2X7 receptor in infection and inflammation2017 · Immunity · PMID 28626215Open reference}9.

Therapeutic Strategies

1. Selective antagonism: Small-molecule P2X7 antagonists that penetrate the BBB could reduce neuroinflammation without immunosuppression, since P2X7 is activated only at pathological ATP concentrations

2. Positive allosteric modulators: Enhancing P2X7 channel function (without macropore formation) could augment beneficial phagocytic microglial activity

3. Nanobody approaches: Anti-P2X7 nanobodies (e.g., 13A7) that selectively block macropore formation while preserving channel function offer a precision pharmacology approach

4. Combination with anti-amyloid therapy: P2X7 inhibition + amyloid clearance may provide synergistic benefit by addressing both amyloid pathology and downstream inflammation^{3P2X7 receptor in the brain: role in neuroinflammation and neurodegeneration2020 · Purinergic Signalling · PMID 32165058Open reference}0

Key Interactions

• NLRP3: P2X7-mediated K⁺ efflux is the primary upstream trigger for NLRP3 inflammasome assembly

• Pannexin-1: Forms large-pore channels that amplify ATP release downstream of P2X7 activation

• Caspase-1: Effector protease activated by the P2X7→NLRP3 inflammasome axis

• IL-1β: Primary pro-inflammatory cytokine matured by P2X7/NLRP3/caspase-1 signaling

• TREM2: Counter-regulatory receptor; TREM2 signaling opposes P2X7-driven inflammation

• CD39 / CD73: Ectonucleotidases that degrade extracellular ATP, reducing P2X7 activation

• P2Y12: Complementary purinergic receptor on microglia; P2Y12 mediates chemotaxis while P2X7 mediates inflammation

See Also

• NLRP3 Inflammasome

• Caspase-1 Protein

• Microglia in Neurodegeneration

• Neuroinflammation

• Pannexin-1

• P2RX7 Gene

External Links

• UniProt: Q99572

• NCBI Gene: P2RX7

• PDB: 5U1L

• OMIM: 602566

Brain Atlas Resources

• Allen Human Brain Atlas - P2RX7 Expression

• Allen Cell Type Atlas

• BrainSpan Atlas of the Developing Human Brain